Name:
Cytokines in immunotherapy
Description:
Cytokines in immunotherapy
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/c5585408-d159-42c1-be2c-00190588dd0d/videoscrubberimages/Scrubber_126.jpg
Duration:
T00H03M02S
Embed URL:
https://stream.cadmore.media/player/c5585408-d159-42c1-be2c-00190588dd0d
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/c5585408-d159-42c1-be2c-00190588dd0d/BTN Cytokine IF - V6.mp4?sv=2019-02-02&sr=c&sig=hTTW8hg5v9XWpF%2FvppN969mUToSdVKC5q3FBjGtA21E%3D&st=2024-11-21T09%3A12%3A45Z&se=2024-11-21T11%3A17%3A45Z&sp=r
Upload Date:
2024-11-21T09:17:45.3720585Z
Transcript:
Language: EN.
Segment:0 .
Cytokines are a large group of bioactive small molecule proteins synthesized and secreted by immune cells like macrophages, B and T lymphocytes, granulocytes and mast cells, as well as certain non immune cells, such as endothelial cells and fibroblasts upon stimulation. There are different types of cytokines, including interleukins, interferons chemokines, tumor necrosis factors, colony stimulating factors, transforming growth factors and growth factors, which fall into different families and serve different roles in the immune system to keep it functioning properly.
Immune cells are crucial tools that help the immune system fight cancer. Cytokines regulate the growth, proliferation and differentiation of immune cells and other cells. As a result, cytokines have become indispensable tools for in vitro cultivation of various cell types, such as immune cells, stem cells and organoids. Cytokines signal the immune system and regulate the body's response to infection and disease, including cancer.
These characteristics mean that cytokines and their receptors can be used in immunotherapy acting as messengers for cancer immune responses. Just two cytokines are approved by the US FDA for the treatment of malignant diseases. Interferon alpha was approved in 1986 for the treatment of hairy cell leukemia and later for follicular non-hodgkin's lymphoma, melanoma and AIDS related.
Kaposi's sarcoma, while interleukin 2 was first approved in 1992 and can be used to treat advanced renal cell carcinoma and metastatic melanoma. However, the clinical application of cytokines is limited by their short half life in vivo, severe toxicity and poor efficacy. To address these challenges, several cytokine engineering strategies have been developed, including Fc fusion, polyethylene glycol conjugation and antibody cytokine fusions aiming to reduce toxicity and improve efficacy.
To aid the research and development of immunotherapies, Sino Biological offers a comprehensive range of high quality GMP and RUO grade cytokines and growth factors characterized by validated bioactivity, Batch to batch consistency and purity. These products play a pivotal role in cell cultures and drug development, advancing the research and development of immunotherapy. To find out more about cytokines for immunotherapy, check out our Focus with Sino Biological on www.biotechniques.com.